{"title":"Clinical Pharmacology of Therapeutic Antibodies for Precision Medicine","authors":"A. Yonezawa","doi":"10.3999/JSCPT.48.99","DOIUrl":"https://doi.org/10.3999/JSCPT.48.99","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"4 1","pages":"99-103"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89235158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Quantitative Analysis of Perception Changes in Clinical Trial Participants During Clinical Trials","authors":"Asumi Kojima, S. Yamazaki, T. Yoshio","doi":"10.3999/JSCPT.48.41","DOIUrl":"https://doi.org/10.3999/JSCPT.48.41","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"38 1","pages":"41-49"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89706379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Kimura, M. Yono, Y. Inoue, K. Furukawa, Mai Fujiyama, T. Oyama, M. Hori, S. Tsuji, Takanori Tanaka, S. Irie
Antagonists for Lower Urinary Tract Symptoms Although doxazosin, a subtype nonselective a 1 -adrenoceptor antagonist, has been shown to improve hypertension and benign prostatic hyperplasia, it is recommended that the two disease entities should be treated independently with the best available drugs. Therefore, we compared the efficacy and safety of three a 1 -adrenoceptor antagonists with different selectivity for the a 1 -adrenoceptor subtypes; doxazosin, silodosin and tamsulosin, for lower urinary tract symptoms in male patients with hypertension and benign prostatic hyperplasia. In a retrospective study, the medical records of 58 hypertensive patients with benign prostatic hyperplasia treated with doxazosin, silodosin plus amlodipine, or tamsulosin plus amlodipine between January 2013 and December 2015 were evaluated. International Prostate Symptom Score ( I-PSS ) , QOL score and maximum urinary flow rate were assessed at baseline and after a 12-week treatment period in all patients. Treatment with doxazosin and amlodipine resulted in a significant reduction in blood pressure from baseline. Doxazosin, silodosin and tamsulosin were similarly effective in improving total I-PSS, QOL score and maximum urinary flow rate. While dizziness was reported in 1 of the 21 patients receiving doxazosin, abnormal ejaculation was reported with subtype selective a 1 -adrenoceptor antagonists but not with doxazosin. Our data demonstrate that all three a 1 -adrenoceptor antagonists have similar clinical efficacy and that there are slight differences in the adverse event profiles of these drugs. These findings suggest that doxazosin is a safe and effective treatment in hypertensive patients with benign prostatic hyperplasia.
{"title":"A Retrospective Clinical Comparison of Subtype Nonselective and Selective α 1 -Adrenoceptor Antagonists for Lower Urinary Tract Symptoms in Male Patients with Hypertension and Benign Prostatic Hyperplasia","authors":"M. Kimura, M. Yono, Y. Inoue, K. Furukawa, Mai Fujiyama, T. Oyama, M. Hori, S. Tsuji, Takanori Tanaka, S. Irie","doi":"10.3999/JSCPT.48.1","DOIUrl":"https://doi.org/10.3999/JSCPT.48.1","url":null,"abstract":"Antagonists for Lower Urinary Tract Symptoms Although doxazosin, a subtype nonselective a 1 -adrenoceptor antagonist, has been shown to improve hypertension and benign prostatic hyperplasia, it is recommended that the two disease entities should be treated independently with the best available drugs. Therefore, we compared the efficacy and safety of three a 1 -adrenoceptor antagonists with different selectivity for the a 1 -adrenoceptor subtypes; doxazosin, silodosin and tamsulosin, for lower urinary tract symptoms in male patients with hypertension and benign prostatic hyperplasia. In a retrospective study, the medical records of 58 hypertensive patients with benign prostatic hyperplasia treated with doxazosin, silodosin plus amlodipine, or tamsulosin plus amlodipine between January 2013 and December 2015 were evaluated. International Prostate Symptom Score ( I-PSS ) , QOL score and maximum urinary flow rate were assessed at baseline and after a 12-week treatment period in all patients. Treatment with doxazosin and amlodipine resulted in a significant reduction in blood pressure from baseline. Doxazosin, silodosin and tamsulosin were similarly effective in improving total I-PSS, QOL score and maximum urinary flow rate. While dizziness was reported in 1 of the 21 patients receiving doxazosin, abnormal ejaculation was reported with subtype selective a 1 -adrenoceptor antagonists but not with doxazosin. Our data demonstrate that all three a 1 -adrenoceptor antagonists have similar clinical efficacy and that there are slight differences in the adverse event profiles of these drugs. These findings suggest that doxazosin is a safe and effective treatment in hypertensive patients with benign prostatic hyperplasia.","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"12 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81529028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Report of the 2nd Annual Meeting of the Kinki Region of the JSCPT","authors":"Yoichi Yamamoto","doi":"10.3999/jscpt.48.181","DOIUrl":"https://doi.org/10.3999/jscpt.48.181","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"31 24","pages":"181-184"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91404518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"4. Drug Development for Refractory Pediatric Intrahepatic Cholestasis by Drug-Repositioning","authors":"Hisamitsu Hayashi","doi":"10.3999/JSCPT.48.117","DOIUrl":"https://doi.org/10.3999/JSCPT.48.117","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"1 1","pages":"117-119"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86255170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"6．Adverse Effects on Brain Function of Psychotropic Drugs, Corticosteroids and Interferon","authors":"K. Kaneko","doi":"10.3999/JSCPT.48.84","DOIUrl":"https://doi.org/10.3999/JSCPT.48.84","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"51 1","pages":"84-90"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84579403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Investigation of the Development History and Status of Risk Identification for Drugs that Received First Global Approved in Japan","authors":"Yuhei Kanda, Akane Takayama, M. Narukawa","doi":"10.3999/JSCPT.48.9","DOIUrl":"https://doi.org/10.3999/JSCPT.48.9","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"41 1","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90900581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Timing of Decision-Making and Informed Consent ： Patients' Perspective and Experiences of Clinical Trials in Japan","authors":"H. Nakada, Sachie Yoshida, E. Arita, K. Muto","doi":"10.3999/JSCPT.48.31","DOIUrl":"https://doi.org/10.3999/JSCPT.48.31","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"14 1","pages":"31-39"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78306136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Katsuno, A. Hashizume, Harumasa Nakamura, K. Ono, K. Yuji, M. Yamada, Takuya Watanabe, K. Ichimaru, Naoto Kato, Takahiro Inoue, M. Kusama, H. Mizushima, Y. Fujimoto, M. Akimoto, Kiyoshi Kobayashi, K. Ohwaki, Koji Uesugi
{"title":"Patient Registry and Biobank for Reverse Translational Research on Neurodegenerative Diseases","authors":"M. Katsuno, A. Hashizume, Harumasa Nakamura, K. Ono, K. Yuji, M. Yamada, Takuya Watanabe, K. Ichimaru, Naoto Kato, Takahiro Inoue, M. Kusama, H. Mizushima, Y. Fujimoto, M. Akimoto, Kiyoshi Kobayashi, K. Ohwaki, Koji Uesugi","doi":"10.3999/JSCPT.48.141","DOIUrl":"https://doi.org/10.3999/JSCPT.48.141","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"46 1","pages":"141-147"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76290183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"2. Drug Development for Hereditary Protein Misfolding Diseases","authors":"H. Kai, M. Suico, T. Shuto","doi":"10.3999/JSCPT.48.110","DOIUrl":"https://doi.org/10.3999/JSCPT.48.110","url":null,"abstract":"","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"23 1","pages":"110-113"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88851054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：